Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)went up by 14.72% from its latest closing price when compared to the 1-year high value of $4.25 and move down -372.22%, while ADMP stocks collected +11.93% of gains with the last five trading sessions. Press Release reported on 09/03/19 that Adamis Pharmaceuticals Provides Update for Naloxone Product Candidate

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Worth an Investment?

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) The 36 Months beta value for ADMP stocks is at 1.36, while of the analysts out of 0 who provided ratings for Adamis Pharmaceuticals Corporation stocks as a “buy” while as overweight, rated it as hold and as sell. The average price we get from analysts is $3.53 which is $2.47 above current price. ADMP currently has a short float of 7.48% and public float of 58.44M with average trading volume of 567.74K shares.

ADMP Market Performance

ADMP stocks went up by 11.93% for the week, with the monthly drop of -18.92% and a quarterly performance of -37.93%, while its annual performance rate touched -71.43%. The simple moving average for the period of the last 20 days is -5.54% for ADMP stocks with the simple moving average of -55.03% for the last 200 days.

Analysts’ Opinion on Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)

Many brokerage firms have already submitted their reports for ADMP stocks, with B. Riley FBR repeating the rating for ADMP shares by setting it to “Sell”. The predicted price for ADMP socks in the upcoming period according to B. Riley FBR is $1.10 based on the research report published on July 16, 2019.

B. Riley FBR, on the other hand, stated in their research note that they expect to see ADMP stock at the price of $2.50, previously predicting the value of $7.50. The rating they have provided for ADMP stocks is “Neutral” according to the report published on November 12, 2018.

Maxim Group gave “Buy” rating to ADMP stocks, setting the target price at $10 in the report published on May 11, 2018.

ADMP Stocks -17.93% Far from 50 Day Moving Average

After a stumble in the market that brought ADMP to its low price for the period of the last 52 weeks, Adamis Pharmaceuticals Corporation was unable to take a rebound, for now settling with -78.82% of loss for the given period.

The stock volatility was left at 7.95%, however, within the period of a single month, the volatility rate increased by 10.91%, while the shares sank at the distance of -21.74% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by -31.82% lower at the present time.

In the course of the last 5 trading sessions, ADMP went up by +11.93%, which changed the moving average for the period of 200 days to the total of -64.71% of losses for the stock in comparison to the 20-day moving average settled at $0.94. In addition, Adamis Pharmaceuticals Corporation saw -60.00% in overturn over the period of a single year with a tendency to cut further losses.

ADMP Stock Insider Trading

Reports are indicating that there were more than several insider trading activities at Adamis Pharmaceuticals Corporation (ADMP), starting from CARLO DENNIS J PHD, who sold 10,477 shares at the price of $1.06 back on Aug 19. After this action, Rushing now owns 353,930 shares of Adamis Pharmaceuticals Corporation, valued at $11,117 with the latest closing price.

Hopkins Robert O, the Chief Financial Officer of Adamis Pharmaceuticals Corporation, sold 7,101 shares at the value of $1.06 during a trade that took place back on Aug 19, which means that Hopkins Robert O is holding 333,247 shares at the value of $7,536 based on the most recent closing price.

ADMP Stock Fundamentals

The current profitability levels are settled at -267.47 for the present operating margin and +14.51 for gross margin. The net margin for Adamis Pharmaceuticals Corporation stands at -258.55. Total capital return value is set at -85.96, while invested capital returns managed to touch -87.83. Equity return holds the value -86.00%, with -67.10% for asset returns.

Based on Adamis Pharmaceuticals Corporation (ADMP), the company’s capital structure generated 5.53 points for debt to equity in total, while total debt to capital is set at the value of 5.24.

The value for Enterprise to Sales is 1.51 with debt to enterprise value settled at 0.04. The receivables turnover for Adamis Pharmaceuticals Corporation is 15.20 with the total asset turnover at the value of 0.27. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.21.